Global Mobile Continuous Glucose Monitoring System Market Size By Type (Invasive, Non-invasive (Exfoliation)), By Application (Self/Home Care, Hospital And Clinics), By Region, And Segment Forecasts,...

The Global Mobile Continuous Glucose Monitoring (CGM) System Market was valued at USD 5.6 billion in 2023 and is projected to reach USD 17.9 billion by 2031, growing at a CAGR of 15.5% during the forecast period from 2023 to 2031. The market is experiencing strong growth due to the rising prevalence of diabetes, increasing awareness of glucose management, and the growing adoption of mobile health technologies. Mobile CGM systems provide real-time glucose readings, reducing the need for frequent fingerstick testing and enabling proactive diabetes management through smartphone integration, remote monitoring, and predictive alerts.

Drivers

1. Rising Prevalence of Diabetes Globally

The increasing incidence of Type 1 and Type 2 diabetes is driving the demand for continuous and real-time glucose monitoring solutions, especially among younger and tech-savvy populations.

2. Advancements in Sensor and Wearable Technologies

Technological improvements in biosensors, data analytics, and wearable integration have significantly enhanced the accuracy, comfort, and usability of mobile CGM systems.

3. Growing Adoption of Digital Health and mHealth Platforms

With the increasing penetration of smartphones and mobile applications, mobile CGM systems are becoming a vital part of digital health ecosystems, enabling remote patient monitoring and data-driven clinical decision-making.

Restraints

1. High Cost of CGM Devices and Sensors

The initial and ongoing costs of mobile CGM systems, including sensor replacements and subscriptions, can be prohibitive, particularly in developing regions with limited healthcare reimbursement.

2. Data Privacy and Security Concerns

Mobile CGM systems involve the continuous transmission of sensitive health data, raising concerns about data breaches and cybersecurity in healthcare IoT systems.

Opportunity

1. Expansion in Emerging Economies

As healthcare infrastructure improves in emerging markets, the adoption of mobile CGM systems is expected to rise, especially through government initiatives focused on non-communicable diseases and digital health.

2. Integration with AI and Predictive Analytics

The integration of artificial intelligence for predictive alerts, insulin dosing recommendations, and real-time pattern analysis presents a significant opportunity for improving patient outcomes and system utility.

Market by System Type Insights

The Wearable CGM Systems segment accounted for the largest share in 2023, driven by patient preference for comfort, ease of use, and real-time monitoring. However, Implantable CGM Systems are expected to witness rapid growth during the forecast period due to longer sensor life, reduced calibration needs, and growing clinical adoption.

Market by End-Use Insights

In 2023, the Home Healthcare segment dominated the market with over 45% share, as patients increasingly manage their glucose levels at home using mobile-connected CGMs. The Hospitals & Clinics segment is also expanding, especially for in-patient diabetes care and perioperative monitoring in high-risk patients.

Market by Regional Insights

North America led the global mobile CGM market in 2023 due to a high prevalence of diabetes, favorable reimbursement policies, and the presence of key market players. The Asia-Pacific region is expected to experience the fastest growth, supported by rising diabetes awareness, smartphone penetration, and increasing healthcare investments in countries like India, China, and Japan.

Competitive Scenario

Key players in the Global Mobile CGM System Market include:

Dexcom, Inc.

Abbott Laboratories

Medtronic plc

Senseonics Holdings, Inc.

Ascensia Diabetes Care

GlySens Incorporated

Eversense (Senseonics)

BioTelemetry (Philips)

Medtrum Technologies Inc.

LifeScan, Inc.

These companies are actively engaged in product innovation, FDA approvals, and strategic partnerships. For instance:

In 2023, Dexcom launched the G7 CGM System, featuring improved accuracy and direct smartphone connectivity.

In 2024, Abbott announced global expansion of its FreeStyle Libre 3, enhancing real-time monitoring with a 14-day sensor life.

Medtronic received FDA clearance for its Simplera CGM sensor in 2025, with no need for fingerstick calibration.

Scope of Work – Global Mobile Continuous Glucose Monitoring System Market

Report Metric Details

Market Size (2023) USD 5.6 billion

Projected Market Size (2031) USD 17.9 billion

CAGR (2023–2031) 15.5%

Market Segments By System Type (Wearable, Implantable), End-Use (Home Healthcare, Hospitals & Clinics), Region

Growth Drivers Rising diabetes prevalence, wearable tech advancements, smartphone adoption

Opportunities Expansion in emerging markets, AI integration for predictive alerts

Key Market Developments

2023: Dexcom received CE Mark for G7 in Europe and launched its CGM system with enhanced app interface.

2024: Abbott expanded the global footprint of FreeStyle Libre 3 in Latin America and Asia-Pacific.

2025: Senseonics launched the Eversense E3 system with a six-month implant duration in select markets.

FAQs

1) What is the current market size of the Global Mobile Continuous Glucose Monitoring System Market?

The market was valued at USD 5.6 billion in 2023.

2) What is the major growth driver of the Global Mobile Continuous Glucose Monitoring System Market?

The primary driver is the rising prevalence of diabetes and increasing demand for real-time, mobile-integrated glucose monitoring.

3) Which is the largest region during the forecast period in the Global Mobile Continuous Glucose Monitoring System Market?

North America held the largest market share in 2023.

4) Which segment accounted for the largest market share in Global Mobile Continuous Glucose Monitoring System Market?

The Wearable CGM Systems segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Mobile Continuous Glucose Monitoring System Market?

Key players include Dexcom, Abbott, Medtronic, Senseonics, and Ascensia Diabetes Care.

Let me know if you'd like this in a downloadable format or tailored further for presentation.